New Report Finds CGM is Effective in Managing Type 2 Diabetes in the US

DexCom releases its "State of Type 2 Report" ahead of the American Diabetes Association's 85th Scientific Sessions. The report provides insights into perceptions of diabetes technology from over 400 healthcare professionals and individuals with Type 2 diabetes in the US. Key findings include: 59% of HCPs believe better access to CGM will be the most effective way to manage Type 2 diabetes, and 96% support CGM as the standard of care for those using multiple daily insulin injections.

DexCom, Inc., a leading provider of glucose biosensing technology, has released its "State of Type 2 Report" ahead of the American Diabetes Association's (ADA) 85th Scientific Sessions. The report, which surveyed over 400 healthcare professionals (HCPs) and individuals with Type 2 diabetes in the United States, provides valuable insights into the perceptions and attitudes surrounding diabetes technology.

Key findings from the report include:
- 59% of HCPs believe that better access to Continuous Glucose Monitoring (CGM) will be the most effective way to help people with Type 2 diabetes manage their condition over the next decade [1].
- 96% of providers surveyed in the U.S. agree that CGM should be the standard of care for individuals using multiple daily insulin injections, while 94% agree that CGM should be the standard of care for those on basal insulin [1].
- 100% of U.S. HCPs surveyed recommend CGM in combination with GLP-1 or SGLT2 medication because it has the best expected outcomes for patients [1].
- Better coverage, more education, and training can improve understanding and usage of CGM. Specifically, 60% of U.S. HCPs said additional funding or budget to cover CGM could increase usage among people with Type 2 diabetes [1].

During the ADA conference, DexCom will present extensive clinical data and host compelling presentations, including a panel featuring DexCom Warrior Lance Bass, who will share his experience with CGM technology. The report underscores the growing recognition of CGM as a central tool in the future of Type 2 diabetes care.

References:
[1] https://investors.dexcom.com/news/news-details/2025/Dexcom-Unveils-New-Report-on-Type-2-Diabetes-Management-in-the-U-S--at-ADA-2025/default.aspx
[2] https://www.stocktitan.net/news/DXCM/dexcom-unveils-new-report-on-type-2-diabetes-management-in-the-u-s-0zfddzvcu816.html